On August 4, 2014, FDA issued a draft guidance titled Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act. The draft guidance is intended to help biological product sponsors and applicants in submitting appropriate information to FDA to enable the Agency to make a regulatory determination of the "first licensure" date of a reference biological product. Click here for a Jones Day Commentary on the new draft guidance.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
